Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41,862 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia.
Jiménez C, Chan GG, Xu L, Tsakmaklis N, Kofides A, Demos MG, Chen J, Liu X, Munshi M, Yang G, Castillo JJ, Wiestner A, García-Sanz R, Treon SP, Hunter ZR. Jiménez C, et al. Among authors: xu l. Br J Haematol. 2020 Jun;189(6):1165-1170. doi: 10.1111/bjh.16463. Epub 2020 Feb 27. Br J Haematol. 2020. PMID: 32103491 Free PMC article. Clinical Trial.
The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia.
Moreau AS, Jia X, Patterson CJ, Roccaro AM, Xu L, Sacco A, O'Connor K, Soumerai J, Ngo HT, Hatjiharissi E, Hunter ZR, Ciccarelli B, Manning R, Ghobrial IM, Leleu X, Treon SP. Moreau AS, et al. Among authors: xu l. Br J Haematol. 2008 Sep;142(5):775-85. doi: 10.1111/j.1365-2141.2008.07257.x. Epub 2008 Jun 3. Br J Haematol. 2008. PMID: 18537966 Free article.
Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.
Treon SP, Yang G, Hanzis C, Ioakimidis L, Verselis SJ, Fox EA, Xu L, Hunter ZR, Tseng H, Manning RJ, Patterson CJ, Sheehy P, Turnbull B. Treon SP, et al. Among authors: xu l. Br J Haematol. 2011 Jul;154(2):223-8. doi: 10.1111/j.1365-2141.2011.08726.x. Epub 2011 May 12. Br J Haematol. 2011. PMID: 21564078 Free article.
The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells.
Cao Y, Yang G, Hunter ZR, Liu X, Xu L, Chen J, Tsakmaklis N, Hatjiharissi E, Kanan S, Davids MS, Castillo JJ, Treon SP. Cao Y, et al. Among authors: xu l. Br J Haematol. 2015 Jul;170(1):134-8. doi: 10.1111/bjh.13278. Epub 2015 Jan 12. Br J Haematol. 2015. PMID: 25582069 Free article. No abstract available.
Ibrutinib in previously treated Waldenström's macroglobulinemia.
Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH. Treon SP, et al. Among authors: xu l. N Engl J Med. 2015 Apr 9;372(15):1430-40. doi: 10.1056/NEJMoa1501548. N Engl J Med. 2015. PMID: 25853747 Free article. Clinical Trial.
Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.
Xu L, Hunter ZR, Tsakmaklis N, Cao Y, Yang G, Chen J, Liu X, Kanan S, Castillo JJ, Tai YT, Zehnder JL, Brown JR, Carrasco RD, Advani R, Sabile JM, Argyropoulos K, Lia Palomba M, Morra E, Trojani A, Greco A, Tedeschi A, Varettoni M, Arcaini L, Munshi NM, Anderson KC, Treon SP. Xu L, et al. Br J Haematol. 2016 Mar;172(5):735-44. doi: 10.1111/bjh.13897. Epub 2015 Dec 13. Br J Haematol. 2016. PMID: 26659815 Free PMC article.
41,862 results
You have reached the last available page of results. Please see the User Guide for more information.